Korea signals,
read at source.
Selected market briefs from Nathan Research Group's Seoul desk, built from local filings, primary-source interviews, and operator context.
The blade, not the razor.
CLASSYS sells skin-tightening devices to clinics at razor-thin economics, then earns for years on the single-use cartridges every treatment burns. Revenue tripled in five years while operating margin never left 50% — the exact trick the Western rivals who sold 'just the machine' couldn't manage. Two of them went bankrupt proving it.
Jun 8, 2026 / 8 min read
→
AgribusinessEverything but the price.
Harim owns every link — the feed mills, four hatcheries, six hundred farms, the most automated slaughterhouse in Asia. Across fifty-four quarters its average operating margin is 0.6%, the lowest of Korea's top-500 food companies. A story about why owning the whole chain is not the same as owning the part that sets the price — and the ₩412 billion the wider group is spending to escape it.
Jun 8, 2026 / 9 min read
→
SemiconductorsThe Rubin reset.
SK Hynix booked ₩52.6T in Q1 2026 at a 72% operating margin. Samsung's first HBM4 shipments to NVIDIA's Vera Rubin landed in February. TrendForce now models Rubin at 22% of NVIDIA's 2026 mix, down from 29%. The Korean duopoly is intact — but the swing variable for the rest of 2026 is no longer share, it is qualified yield into a delayed flagship.
May 8, 2026 / 9 min read
→
Bio & PharmaKorea's GLP-1 lane opens.
Celltrion booked ₩1.15 trillion in Q1 2026 at a 28% operating margin — its best quarter on record. Samsung Biologics ran its first commercial-scale ADC engineering batch at Songdo. A new three-party joint venture put long-acting GLP-1 obesity drugs squarely on the Korean roadmap. The catch-up framing is officially obsolete.
May 7, 2026 / 8 min read
→Trusted by global institutions.
01Private Equity & Venture Capital
500+PE/VC engagements
02Hedge Funds & Asset Managers
50+Hedge fund clients
03Management Consultancies
Top 10Firms served
04Corporate Strategy Teams
200+Strategy projects
05Investment Banks
100+M&A engagements
From deal sourcing to post-acquisition value creation, access Korean industry experts who accelerate your due diligence and portfolio strategy.
Ready to access Korea’s deepest expert network?
Tell us about your research needs. Our Seoul-based team responds within one business day.
We value your privacy
We use cookies to understand how our site is used so we can improve it. Necessary cookies are always on. You can accept all, reject all, or choose what to allow. Learn more